Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-12-28Clinical Trial Update: A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) [Phase 3]
A Phase 3 pediatric study evaluating mirabegron for overactive bladder in participants aged 5 to under 18 was terminated, and results have b…
-
CLINICAL_TRIALS trial_result · 2023-11-02Clinical Trial Update: Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection [Phase 4]
Phase 4 trial comparing prevention methods for urinary tract infections after Botox injections for overactive bladder; terminated with resul…
-
CLINICAL_TRIALS trial_result · 2023-10-13Clinical Trial Update: Is 10 Injections of Bladder Botox Less Painful Than 20 Injections? [Phase 4]
Phase 4 trial comparing pain between 10 versus 20 injections of bladder Botox for overactive bladder; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2023-09-15Clinical Trial Update: Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin [Phase 3]
Phase 3 trial comparing mirabegron to solifenacin for pharmacologic effect in female overactive bladder syndrome.
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study [Phase 4]
A Phase 4 randomized trial compares monotherapy with mirabegron or tolterodine to combined mirabegron-tolterodine therapy on autonomic funct…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-08-14Clinical Trial Update: Sham Controlled Trial of Rapid Induction Percutaneous Tibial Nerve Stimulation [NA]
A sham-controlled trial of rapid induction percutaneous tibial nerve stimulation for overactive bladder has completed recruitment with resul…
-
CLINICAL_TRIALS trial_result · 2023-07-20Clinical Trial Update: Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study) [Phase 4]
A Phase 4 trial evaluating PTNS plus mirabegron for refractory overactive bladder has completed with results posted.
-
FDA approval · 2023-06-07FDA Approved: TOLTERODINE TARTRATE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for Tolterodine Tartrate (generic) submitted by Macleods Pharmaceuticals Limited.
-
FDA approval · 2023-05-24FDA Approved: OXYBUTYNIN CHLORIDE EXTENDED RELEASE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for oxybutynin chloride extended-release by Rising Pharma Holdings, Inc., confirming the product and…
-
CLINICAL_TRIALS trial_result · 2023-03-29Clinical Trial Update: A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder [Phase 4]
A Phase 4 study evaluating mirabegron at 50 mg and 25 mg in Chinese participants with overactive bladder has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2023-03-16Clinical Trial Update: A Safety Extension Study of DR-OXY-301 [Phase 3]
Phase 3 safety extension study update for DR-OXY-301 in overactive bladder.
-
FDA approval · 2023-02-27FDA Approved: FESOTERODINE FUMARATE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for fesoterodine fumarate by Zydus Pharmaceuticals USA Inc., granting approval for a generic fes…
-
FDA approval · 2023-02-27FDA Approved: FESOTERODINE FUMARATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for fesoterodine fumarate from Aurobindo Pharma Limited, a generic treatment for overactive bladder.
-
FDA approval · 2023-02-02FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Accord Healthcare, Inc.)
FDA approved a supplemental application for oxybutynin chloride from Accord Healthcare, Inc.
-
FDA approval · 2023-02-02FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for oxybutynin chloride by Amneal Pharmaceuticals, updating the approved product under an abbreviate…
-
FDA approval · 2023-01-27FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Advagen Pharma Limited)
FDA approved a supplemental application for oxybutynin chloride from Advagen Pharma Limited.
-
FDA approval · 2023-01-04FDA Approved: FESOTERODINE FUMARATE — Original Application (Amneal Pharmaceuticals LLC)
FDA approval of Amneal's fesoterodine fumarate original application, a generic oral medication for overactive bladder.
-
FDA approval · 2023-01-04FDA Approved: FESOTERODINE FUMARATE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals Inc.'s original application for fesoterodine fumarate, a generic treatment for overactive bladder.
-
CLINICAL_TRIALS trial_result · 2022-12-28Clinical Trial Update: OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17) [Phase 3]
Phase 3 trial evaluating onabotulinumtoxinA for urinary incontinence due to overactive bladder in pediatric patients aged 12 to 17 was termi…
-
FDA approval · 2022-12-27FDA Approved: SOLIFENACIN SUCCINATE — Original Application (Aurobindo Pharma Limited)
FDA approves the original application for solifenacin succinate (generic) by Aurobindo Pharma Limited as a treatment option for overactive b…
-
CLINICAL_TRIALS trial_result · 2022-12-22Clinical Trial Update: Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB) [Phase 2]
Phase 2 clinical study evaluating BAY1817080 for safety and treatment effect in adults with Overactive Bladder has been completed.
-
FDA approval · 2022-10-07FDA Approved: TROSPIUM CHLORIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
The FDA approved a supplemental application for trospium chloride from Granules Pharmaceuticals Inc. under ANDA213185. This confirms approva…
-
FDA approval · 2022-09-29FDA Approved: MIRABEGRON — Original Application (Zydus Pharmaceuticals (USA) Inc.)
FDA approved the original generic application for mirabegron, enabling Zydus Pharmaceuticals (USA) Inc. to market the generic form of mirabe…
-
FDA approval · 2022-09-28FDA Approved: MIRABEGRON — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approves Lupin's MIRABEGRON for the treatment of overactive bladder.
-
CLINICAL_TRIALS trial_result · 2022-09-22Clinical Trial Update: The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder [Phase 3]
A Phase 3 clinical trial investigating whether using a local anesthetic solution in the bladder before Botox injections affects outcomes in …